Study #ALLIANCEA071102-NO
ALLIANCEA071102-NO: A PHASE II/III RANDOMIZED TRIAL OF VELIPARIB OR PLACEBO IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMAWITH MGMT PROMOTER HYPERMETHYLATION
MD Anderson Study Status
Not Accepting
Treatment Agent
Temozolomide, Veliparib
Description
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma, Gliosarcoma
Study phase:
Phase II/III
Physician name:
Barbara O'Brien
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-328-3322
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.